Recruiting

BIIB141

Sponsor:

Biogen

Code:

NCT06628687

Conditions

Friedreich Ataxia

Eligibility Criteria

Sex: Female

Age: 16+

Healthy Volunteers: Not accepted

Interventions

Omaveloxolone

Study Details

Brief summary:

In this study, researchers will learn more about the safety of BIIB141, also known as omaveloxolone or SKYCLARYS. This is a drug available for doctors to prescribe for people with Friedrich's Ataxia, also known as FA. This is known as an "observational" study, which collects health information about study participants without changing their medical care. Participants for this study will have taken BIIB141 at any time during pregnancy and/or while breastfeeding or pumping up through the first year after delivery. Participants can join this study on their own or they may be enrolled by their regular doctors. This study is also known as the "SKYCLARYS (Omaveloxolone) Pregnancy and Lactation Surveillance Program."

The main objective of this study is to learn more about how BIIB141 may affect pregnancy, as well as any effects on the health of the mother and of the baby during its first year of life.

The main question researchers want to answer in this study is:

ยท Does taking BIIB141 during pregnancy or breastfeeding lead to any major birth defects?

Researchers will also learn more about:

  • Does taking BIIB141 during pregnancy or breastfeeding lead to any minor birth defects?
  • Does taking BIIB141 during pregnancy or breastfeeding affect the following:
  • Gestational diabetes, a disease that can happen during pregnancy that affects how your body uses sugar
  • Pre-eclampsia, a pregnancy-related high blood pressure disease
  • Unborn baby being small for its expected age (usually in weeks)
  • Loss of an unborn baby
  • Live birth
  • Premature birth
  • Loss of a newborn
  • Growth or developmental delays in the baby
  • Serious illness in the baby resulting in hospitalization
  • Serious infections in the baby, or ones in babies with a weakened immune system

This study will be done as follows:

  • Participants will join the study after signing an informed consent form, also known as an ICF.
  • During the study, health information from the participants' regular visits to their doctor will be collected based on whether participant joined the study while pregnant or after the baby is born.
  • Each participant will be in the study for up to 1 year after the birth of their child, unless they decide to leave early. Overall, this study is expected to last at least 10 years.

Conditions

Friedreich Ataxia

Study ID

NCT06628687

Start date

Oct 26, 2026

Status verified date

Jul, 2026

Completion date

Apr 30, 2035

Anticipated

Primary completion date

Apr 30, 2035

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: Female

Age: 16+

Healthy Volunteers: Not accepted

Key Inclusion Criteria:

\- Exposure to omaveloxolone for FA at any time during pregnancy (from 12 days prior to conception to pregnancy outcome) and/or at any time during lactation (up to 1 year of infant age or weaning, whichever comes first).

Key Exclusion Criteria:

\- Not having exposure to omaveloxolone for FA.

Note: Other protocol-defined Inclusion/Exclusion criteria may apply.

Study Design

Enrollment

10 participants

Anticipated

Interventions and Outcome Measures

Arms

Omaveloxolone

Participants with FA who were exposed to omaveloxolone at any time during pregnancy (from 12 days prior to conception through the end of pregnancy outcome), and/or at any time during lactation (up to 1 year of infant age or weaning, whichever comes first).

Interventions

Omaveloxolone

Administered as specified in the treatment arm.

Primary outcome measure

  • Number of Major Congenital Malformations (MCMs) [ Time Frame: Up to 10 years ]

Central Contacts and Locations

Central contacts

US Biogen Clinical Trial Center

866-633-4636clinicaltrials@biogen.com

Global Biogen Clinical Trial Center

clinicaltrials@biogen.com

Locations

Evidera

Recruiting

Morrisville, North Carolina, United States, 27560

Contacts

Principal Investigator:

Ronna Chan

More Information

Sponsor

Biogen

Last update posted

Jul 10, 2026

Last verified

Jul, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Biogen on 2026-07-10.